| Year |
Citation |
Score |
| 2023 |
Zhu S, Lalani AI, Jin J, Sant'Angelo D, Covey LR, Liu K, Young HA, Ostrand-Rosenberg S, Xie P. The adaptor protein TRAF3 is an immune checkpoint that inhibits myeloid-derived suppressor cell expansion. Frontiers in Immunology. 14: 1167924. PMID 37207205 DOI: 10.3389/fimmu.2023.1167924 |
0.41 |
|
| 2023 |
Ostrand-Rosenberg S, Lamb TJ, Pawelec G. Here, There, and Everywhere: Myeloid-Derived Suppressor Cells in Immunology. Journal of Immunology (Baltimore, Md. : 1950). 210: 1183-1197. PMID 37068300 DOI: 10.4049/jimmunol.2200914 |
0.348 |
|
| 2023 |
Ostrand-Rosenberg S, Huecksteadt T, Sanders K. The Receptor for Advanced Glycation Endproducts (RAGE) and Its Ligands S100A8/A9 and High Mobility Group Box Protein 1 (HMGB1) Are Key Regulators of Myeloid-Derived Suppressor Cells. Cancers. 15. PMID 36831371 DOI: 10.3390/cancers15041026 |
0.356 |
|
| 2021 |
Wuren T, Huecksteadt T, Beck E, Warren K, Hoidal J, Ostrand-Rosenberg S, Sanders K. The receptor for advanced glycation endproducts (RAGE) decreases survival of tumor-bearing mice by enhancing the generation of lung metastasis-associated myeloid-derived suppressor cells. Cellular Immunology. 365: 104379. PMID 34038758 DOI: 10.1016/j.cellimm.2021.104379 |
0.335 |
|
| 2020 |
Fenselau C, Ostrand-Rosenberg S. Molecular cargo in myeloid-derived suppressor cells and their exosomes. Cellular Immunology. 359: 104258. PMID 33338939 DOI: 10.1016/j.cellimm.2020.104258 |
0.344 |
|
| 2019 |
Ostrand-Rosenberg S, Beury DW, Parker KH, Horn LA. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment. Cancer Immunology, Immunotherapy : Cii. PMID 31501954 DOI: 10.1007/S00262-019-02388-8 |
0.49 |
|
| 2019 |
Simon T, Li L, Wagner C, Zhang T, Saxena V, Brinkman CC, Tostanoski LH, Ostrand-Rosenberg S, Jewell C, Shea-Donohue T, Hippen K, Blazar B, Abdi R, Bromberg JS. Differential Regulation of T Cell Immunity and Tolerance by Stromal Laminin Expressed in the Lymph Node. Transplantation. PMID 31343575 DOI: 10.1097/Tp.0000000000002774 |
0.445 |
|
| 2019 |
Pawelec G, Verschoor CP, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Not Only in Tumor Immunity. Frontiers in Immunology. 10: 1099. PMID 31156644 DOI: 10.3389/fimmu.2019.01099 |
0.437 |
|
| 2019 |
Ostrand-Rosenberg S, Horn LA, Ciavattone NG. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy. Frontiers in Oncology. 9: 215. PMID 31001479 DOI: 10.3389/Fonc.2019.00215 |
0.545 |
|
| 2018 |
Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine. PMID 29686425 DOI: 10.1038/S41591-018-0014-X |
0.423 |
|
| 2018 |
Ostrand-Rosenberg S. Myeloid derived-suppressor cells: their role in cancer and obesity. Current Opinion in Immunology. 51: 68-75. PMID 29544121 DOI: 10.1016/J.Coi.2018.03.007 |
0.36 |
|
| 2018 |
Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg S. High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. Journal of Leukocyte Biology. PMID 29345342 DOI: 10.1002/Jlb.4Hi0517-210R |
0.47 |
|
| 2018 |
Ostrand-Rosenberg S, Fenselau C. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. Journal of Immunology (Baltimore, Md. : 1950). 200: 422-431. PMID 29311384 DOI: 10.4049/Jimmunol.1701019 |
0.554 |
|
| 2017 |
Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S, El-Sayed NM, Fenselau C. Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions. Journal of Proteome Research. PMID 29139296 DOI: 10.1021/Acs.Jproteome.7B00646 |
0.52 |
|
| 2017 |
Horn LA, Long TM, Atkinson R, Clements V, Ostrand-Rosenberg S. Soluble CD80 protein delays tumor growth and promotes tumor infiltrating lymphocytes. Cancer Immunology Research. PMID 29122838 DOI: 10.1158/2326-6066.Cir-17-0026 |
0.565 |
|
| 2017 |
Adams KR, Chauhan S, Patel DB, Clements VK, Wang Y, Jay SM, Edwards NJ, Ostrand-Rosenberg S, Fenselau C. Ubiquitin conjugation probed by inflammation in MDSC extracellular vesicles. Journal of Proteome Research. PMID 29061044 DOI: 10.1021/Acs.Jproteome.7B00585 |
0.354 |
|
| 2017 |
Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, Sinha P, Poudel M, Ostrand-Rosenberg S. CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1(+) tumor cells, and extends the survival of tumor-bearing humanized mice. Oncotarget. 8: 57964-57980. PMID 28938530 DOI: 10.18632/Oncotarget.19865 |
0.644 |
|
| 2016 |
Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements VK. Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice. Journal of Leukocyte Biology. PMID 28007981 DOI: 10.1189/Jlb.1Hi1016-306Rr |
0.43 |
|
| 2016 |
Ku AW, Muhitch JB, Powers CA, Diehl MG, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, ... Ostrand-Rosenberg S, et al. Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife. 5. PMID 27929373 DOI: 10.7554/Elife.17375 |
0.512 |
|
| 2016 |
Chauhan S, Danielson S, Clements V, Edwards NJ, Ostrand-Rosenberg S, Fenselau C. Surface glycoproteins of exosomes shed by myeloid-derived suppressor cells contribute to function. Journal of Proteome Research. PMID 27728760 DOI: 10.1021/Acs.Jproteome.6B00811 |
0.379 |
|
| 2016 |
Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nature Communications. 7: 12150. PMID 27381735 DOI: 10.1038/Ncomms12150 |
0.43 |
|
| 2016 |
Choksawangkarn W, Graham LM, Burke M, Lee SB, Ostrand-Rosenberg S, Fenselau C, Edwards NJ. Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways. Proteomics. PMID 27193397 DOI: 10.1002/Pmic.201500102 |
0.423 |
|
| 2016 |
Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2. Journal of Immunology (Baltimore, Md. : 1950). PMID 26936880 DOI: 10.4049/Jimmunol.1501785 |
0.509 |
|
| 2016 |
Parker KH, Horn LA, Ostrand-Rosenberg S. High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy. Journal of Leukocyte Biology. PMID 26864266 DOI: 10.1189/Jlb.3Hi0715-305R |
0.543 |
|
| 2016 |
Ostrand-Rosenberg S. Tolerance and immune suppression in the tumor microenvironment. Cellular Immunology. 299: 23-9. PMID 26435343 DOI: 10.1016/J.Cellimm.2015.09.011 |
0.509 |
|
| 2016 |
Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, ... Ostrand-Rosenberg S, et al. Author response: Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes Elife. DOI: 10.7554/Elife.17375.028 |
0.368 |
|
| 2016 |
Long TM, Ostrand-Rosenberg S. Abstract B017: A soluble form of CD80 inhibits PD-L1 immune suppression and stimulates T cells through CD28-specific pathways indicating potential for increased therapeutic activity over checkpoint inhibition alone Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B017 |
0.528 |
|
| 2016 |
Horn L, Clements V, Ostrand-Rosenberg S. Abstract B013: A soluble form of CD80 enhances anti-tumor immunity by inhibiting PDL1 immune suppression and does not suppress via CTLA-4 Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B013 |
0.562 |
|
| 2015 |
Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Advances in Cancer Research. 128: 95-139. PMID 26216631 DOI: 10.1016/Bs.Acr.2015.04.002 |
0.552 |
|
| 2015 |
Geis-Asteggiante L, Dhabaria A, Edwards N, Ostrand-Rosenberg S, Fenselau C. Top-down analysis of low mass proteins in exosomes shed by murine myeloid-derived suppressor cells. International Journal of Mass Spectrometry. 378: 264-269. PMID 25937807 DOI: 10.1016/J.Ijms.2014.08.035 |
0.329 |
|
| 2015 |
Geng D, Kaczanowska S, Tsai A, Younger K, Ochoa A, Rapoport AP, Ostrand-Rosenberg S, Davila E. TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Research. 75: 1959-71. PMID 25795705 DOI: 10.1158/0008-5472.Can-14-2467 |
0.568 |
|
| 2015 |
Ostrand-Rosenberg S, Horn LA, Alvarez JA. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells. Cancer Immunology, Immunotherapy : Cii. 64: 1287-93. PMID 25792524 DOI: 10.1007/S00262-015-1677-5 |
0.582 |
|
| 2014 |
Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. Journal of Immunology (Baltimore, Md. : 1950). 193: 3835-41. PMID 25281753 DOI: 10.4049/Jimmunol.1401572 |
0.827 |
|
| 2014 |
Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S. Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. Journal of Leukocyte Biology. 96: 1109-18. PMID 25170116 DOI: 10.1189/Jlb.3A0414-210R |
0.446 |
|
| 2014 |
Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Research. 74: 5723-33. PMID 25164013 DOI: 10.1158/0008-5472.Can-13-2347 |
0.601 |
|
| 2014 |
Haile ST, Horn LA, Ostrand-Rosenberg S. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation. Cancer Immunology Research. 2: 610-5. PMID 24819296 DOI: 10.1158/2326-6066.Cir-13-0204 |
0.802 |
|
| 2014 |
Burke M, Choksawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C. Exosomes from myeloid-derived suppressor cells carry biologically active proteins. Journal of Proteome Research. 13: 836-43. PMID 24295599 DOI: 10.1021/Pr400879C |
0.536 |
|
| 2014 |
Muller AJ, Smith C, Chang MY, DuHadaway J, Mondal A, Flick H, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC. Abstract 3665: IDO1 is an integrative determinant of tumor-promoting, pathogenic inflammation Cancer Research. 74: 3665-3665. DOI: 10.1158/1538-7445.Am2014-3665 |
0.508 |
|
| 2014 |
Ostrand-Rosenberg S. Macrophages and tumor development Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal. 185-212. DOI: 10.1007/978-1-4899-8056-4_6 |
0.42 |
|
| 2013 |
Ostrand-Rosenberg S. Inflammation, immune suppression, and tumor progression. Bmc Proceedings. 7: K20. PMID 24764478 DOI: 10.1186/1753-6561-7-S2-K20 |
0.557 |
|
| 2013 |
Sinha P, Ostrand-Rosenberg S. Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract. Cancer Immunology, Immunotherapy : Cii. 62: 1663-73. PMID 23982485 DOI: 10.1007/S00262-013-1470-2 |
0.554 |
|
| 2013 |
Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. Journal of Immunology (Baltimore, Md. : 1950). 191: 2829-36. PMID 23918985 DOI: 10.4049/Jimmunol.1202777 |
0.837 |
|
| 2013 |
Ostrand-Rosenberg S. Looking to the future of cancer immunotherapy: many questions to answer and many therapeutic opportunities. Cancer Immunology, Immunotherapy : Cii. 62: 1-2. PMID 23254777 DOI: 10.1007/S00262-012-1383-5 |
0.448 |
|
| 2013 |
Sinha P, Ostrand-Rosenberg S. Abstract 4718: Withaferin A, a potent and abundant component of Withania somnifera root extract, reduces myeloid-derived suppressor cell function. Cancer Research. 73: 4718-4718. DOI: 10.1158/1538-7445.Am2013-4718 |
0.564 |
|
| 2013 |
Haile S, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Abstract 462: Soluble CD80 restores T-cell activation and overcomes tumor cell programmed death ligand-1-mediated suppression. Cancer Research. 73: 462-462. DOI: 10.1158/1538-7445.Am2013-462 |
0.84 |
|
| 2013 |
Beury DW, Parker KH, Ostrand-Rosenberg S. Abstract 2876: Inflammation of the tumor microenvironment is regulated by myeloid derived suppressor cell and macrophage crosstalk. Cancer Research. 73: 2876-2876. DOI: 10.1158/1538-7445.Am2013-2876 |
0.361 |
|
| 2013 |
Dalal SP, Haile S, Somasundaram P, Ostrand-Rosenberg S. Abstract 1264: Mutated CD80 may facilitate T-cell activation by inhibiting PDL1-PD1 suppression and by costimulating. Cancer Research. 73: 1264-1264. DOI: 10.1158/1538-7445.Am2013-1264 |
0.809 |
|
| 2013 |
Ostrand-Rosenberg S, Sinha P, Beury DW, Chornoguz O, Parker KH. Tumor-induced Myeloid-derived Suppressor Cells Cancer Immunotherapy: Immune Suppression and Tumor Growth: Second Edition. 473-496. DOI: 10.1016/B978-0-12-394296-8.00028-2 |
0.824 |
|
| 2013 |
Ostrand-Rosenberg S, Sinha P. Inflammation, tumor progression, and immune suppression The Tumor Immunoenvironment. 2147483647: 177-196. DOI: 10.1007/978-94-007-6217-6_7 |
0.431 |
|
| 2012 |
Chornoguz O, Gapeev A, O'Neill MC, Ostrand-Rosenberg S. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients. Molecular & Cellular Proteomics : McP. 11: 1457-67. PMID 22942358 DOI: 10.1074/Mcp.M112.019232 |
0.788 |
|
| 2012 |
Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discovery. 2: 722-35. PMID 22822050 DOI: 10.1158/2159-8290.Cd-12-0014 |
0.399 |
|
| 2012 |
Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα. European Journal of Immunology. 42: 2052-9. PMID 22673957 DOI: 10.1002/Eji.201142230 |
0.342 |
|
| 2012 |
Ostrand-Rosenberg S, Sinha P, Chornoguz O, Ecker C. Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunology, Immunotherapy : Cii. 61: 1319-25. PMID 22546994 DOI: 10.1007/S00262-012-1269-6 |
0.812 |
|
| 2012 |
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology. 12: 253-68. PMID 22437938 DOI: 10.1038/Nri3175 |
0.45 |
|
| 2012 |
Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars in Cancer Biology. 22: 275-81. PMID 22313874 DOI: 10.1016/J.Semcancer.2012.01.011 |
0.56 |
|
| 2012 |
Smith C, Chang M, Flick H, DuHadaway J, Mandik-Nayak L, Laury-Kleintop L, Parker K, Beury D, Ostrand-Rosenberg S, Prendergast GC, Muller AJ. Abstract 295: IDO drives tumor-promoting, pathogenic inflammation in lung Cancer Research. 72: 295-295. DOI: 10.1158/1538-7445.Am2012-295 |
0.458 |
|
| 2012 |
Prendergast GC, Metz R, Chang MY, Smith C, Muller AJ, Ostrand-Rosenberg S. Indoleamine 2,3-dioxygenase amino acid metabolism and tumour-associated macrophages: regulation in cancer-associated inflammation and immune escape Tumour-Associated Macrophages. 2147483647: 91-104. DOI: 10.1007/978-1-4614-0662-4_7 |
0.362 |
|
| 2011 |
Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. The Journal of Biological Chemistry. 286: 23591-9. PMID 21592961 DOI: 10.1074/Jbc.M111.237123 |
0.59 |
|
| 2011 |
Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. Journal of Immunology (Baltimore, Md. : 1950). 186: 6822-9. PMID 21555531 DOI: 10.4049/Jimmunol.1003682 |
0.851 |
|
| 2011 |
Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 117: 5381-90. PMID 21450901 DOI: 10.1182/Blood-2010-11-321752 |
0.836 |
|
| 2011 |
Chornoguz O, Grmai L, Sinha P, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Molecular & Cellular Proteomics : McP. 10: M110.002980. PMID 21191032 DOI: 10.1074/Mcp.M110.002980 |
0.79 |
|
| 2011 |
Ostrand-Rosenberg S, Celis E, Cohen P, Eshher Z, Gendler S, Hoelzinger D, Hurwitz A, Pease L, Sherman L. Obituary: Joseph Lustgarten, 1963-2011 Cancer Immunology, Immunotherapy. 1-2. DOI: 10.1007/S00262-011-1080-9 |
0.511 |
|
| 2010 |
Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. European Journal of Immunology. 40: 3347-57. PMID 21110318 DOI: 10.1002/Eji.201041037 |
0.488 |
|
| 2010 |
van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes. Cancer Immunology, Immunotherapy : Cii. 59: 1825-38. PMID 20820776 DOI: 10.1007/S00262-010-0908-Z |
0.358 |
|
| 2010 |
Srivastava MK, Bosch JJ, Wilson AL, Edelman MJ, Ostrand-Rosenberg S. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. International Journal of Cancer. 127: 2612-21. PMID 20473949 DOI: 10.1002/Ijc.25462 |
0.69 |
|
| 2010 |
Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunology, Immunotherapy : Cii. 59: 1593-600. PMID 20414655 DOI: 10.1007/S00262-010-0855-8 |
0.554 |
|
| 2010 |
Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Research. 70: 68-77. PMID 20028852 DOI: 10.1158/0008-5472.Can-09-2587 |
0.666 |
|
| 2010 |
van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses. Haematologica. 95: 485-93. PMID 19903675 DOI: 10.3324/Haematol.2009.010595 |
0.443 |
|
| 2010 |
Bosch JJ, Iheagwara UK, Reid S, Srivastava MK, Wolf J, Lotem M, Ksander BR, Ostrand-Rosenberg S. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunology, Immunotherapy : Cii. 59: 103-12. PMID 19557412 DOI: 10.1007/S00262-009-0729-0 |
0.692 |
|
| 2010 |
Chornoguz OY, Grmail L, Sinha P, Artemenko K, Zubarev R, Ostrand-Rosenberg S. Abstract 5316: Inflammation-induced myeloid-derived suppressor cells have enhanced resistance to apoptosis Cancer Research. 70: 5316-5316. DOI: 10.1158/1538-7445.Am10-5316 |
0.433 |
|
| 2010 |
Sinha P, Chornoguz O, Clements VK, Artemenko K, Zubarev RA, Ostrand-Rosenberg S. Abstract 5312: Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL Cancer Research. 70: 5312-5312. DOI: 10.1158/1538-7445.Am10-5312 |
0.827 |
|
| 2010 |
Haile ST, Bosch J, Agu N, Ostrand-Rosenberg S. Abstract 5309: Programmed Death Ligand-1 expression on the cell surface is regulated by Costimulatory Molecule CD80 expressed by cancer vaccines Cancer Research. 70: 5309-5309. DOI: 10.1158/1538-7445.Am10-5309 |
0.832 |
|
| 2010 |
Kolovou PE, Trichonas G, Frank NY, Murray TG, O'Brien JM, Ostrand-Rosenberg S, Vavvas D, Frank MH, Ksander BR. Abstract 4363: Identification of ABCB5 multidrug transporter in retinoblastoma Cancer Research. 70: 4363-4363. DOI: 10.1158/1538-7445.Am10-4363 |
0.476 |
|
| 2010 |
Beury DW, Fitzgerald P, Srivastava MK, Ostrand-Rosenberg S. Abstract 1922: Do stress response genes play a role in maintaining MDSC survival and suppression Cancer Research. 70: 1922-1922. DOI: 10.1158/1538-7445.Am10-1922 |
0.657 |
|
| 2009 |
Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 183: 937-44. PMID 19553533 DOI: 10.4049/Jimmunol.0804253 |
0.569 |
|
| 2009 |
Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology (Baltimore, Md. : 1950). 182: 4499-506. PMID 19342621 DOI: 10.4049/Jimmunol.0802740 |
0.519 |
|
| 2009 |
Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. Journal of Leukocyte Biology. 85: 996-1004. PMID 19261929 DOI: 10.1189/Jlb.0708446 |
0.549 |
|
| 2009 |
Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Research and Treatment. 117: 235-42. PMID 18792778 DOI: 10.1007/S10549-008-0180-5 |
0.478 |
|
| 2009 |
van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Low CLIP Expression On Leukemic Blasts From AML Patients Is Essential for the Generation of Effective CD4+ T Cell Responses. Blood. 114: 996-996. DOI: 10.1182/Blood.V114.22.996.996 |
0.543 |
|
| 2009 |
van Luijn MM, Chamuleau ME, Ressing ME, Wiertz EJ, Ostrand-Rosenberg S, Souwer Y, Zevenbergen A, Ossenkoppele GJ, van de Loosdrecht AA, van Ham SM. Myeloid Leukemic Blasts Use the Endogenous HLA Class I Antigen Processing Machinery for Peptide Loading Onto HLA Class II Molecules: Implications for Immunotherapy. Blood. 114: 3114-3114. DOI: 10.1182/Blood.V114.22.3114.3114 |
0.387 |
|
| 2008 |
Ostrand-Rosenberg S. Cancer and complement. Nature Biotechnology. 26: 1348-9. PMID 19060872 DOI: 10.1038/Nbt1208-1348 |
0.458 |
|
| 2008 |
Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. Journal of Immunology (Baltimore, Md. : 1950). 181: 4666-75. PMID 18802069 DOI: 10.4049/Jimmunol.181.7.4666 |
0.527 |
|
| 2008 |
Srivastava MK, Bosch JJ, Thompson JA, Ksander BR, Edelman MJ, Ostrand-Rosenberg S. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunology, Immunotherapy : Cii. 57: 1493-504. PMID 18322683 DOI: 10.1007/S00262-008-0490-9 |
0.75 |
|
| 2008 |
Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Current Opinion in Genetics & Development. 18: 11-8. PMID 18308558 DOI: 10.1016/J.Gde.2007.12.007 |
0.461 |
|
| 2008 |
Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunology, Immunotherapy : Cii. 57: 389-98. PMID 17724589 DOI: 10.1007/S00262-007-0381-5 |
0.72 |
|
| 2008 |
van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Modification of Invariant Chain and CLIP Expression Increases the Immunogenicity of Leukemic Blasts to Potentiate Leukemia-Specific T Cell Reactivity Blood. 112: 5430-5430. DOI: 10.1182/blood.v112.11.5430.5430 |
0.416 |
|
| 2008 |
Ostrand-Rosenberg S, Sinha P, Clements V, Bunt S, Srivastava M. Abstract PL03-02: Inflammation-driven myeloid-derived suppressor cells: co-opting anti-tumor immunity to promote tumor progression Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Pl03-02 |
0.524 |
|
| 2007 |
Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Research. 67: 10019-26. PMID 17942936 DOI: 10.1158/0008-5472.Can-07-2354 |
0.453 |
|
| 2007 |
Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. Journal of Immunology (Baltimore, Md. : 1950). 179: 977-83. PMID 17617589 DOI: 10.4049/Jimmunol.179.2.977 |
0.478 |
|
| 2007 |
Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Research. 67: 4507-13. PMID 17483367 DOI: 10.1158/0008-5472.Can-06-4174 |
0.523 |
|
| 2007 |
Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Research. 67: 4499-506. PMID 17483366 DOI: 10.1158/0008-5472.Can-06-3770 |
0.731 |
|
| 2007 |
Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Research. 67: 425; author reply 42. PMID 17210725 DOI: 10.1158/0008-5472.Can-06-3037 |
0.432 |
|
| 2007 |
van Luijn MM, Chamuleau ME, Westers TM, Thompson JA, Ostrand-Rosenberg S, Ossenkoppele GJ, van Ham SM, Van de Loosdrecht AA. Class-II Associated Invariant Chain Peptide (CLIP) Expression on AML Blasts Adversely Affects Alloreactive CD4+ T Cell Recognition. Blood. 110: 4888-4888. DOI: 10.1182/Blood.V110.11.4888.4888 |
0.56 |
|
| 2007 |
Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, Ostrand-Rosenberg S. Tumor-Associated Myeloid-Derived Suppressor Cells Cancer Immunotherapy. 309-331. DOI: 10.1016/B978-012372551-6/50081-X |
0.706 |
|
| 2006 |
Dolan BP, Gibbs KD, Ostrand-Rosenberg S. Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 177: 6018-24. PMID 17056526 DOI: 10.4049/Jimmunol.177.9.6018 |
0.501 |
|
| 2006 |
Dolan BP, Gibbs KD, Ostrand-Rosenberg S. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Journal of Immunology (Baltimore, Md. : 1950). 176: 1447-55. PMID 16424172 DOI: 10.4049/Jimmunol.176.3.1447 |
0.562 |
|
| 2006 |
Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Research. 66: 1147-54. PMID 16424052 DOI: 10.1158/0008-5472.Can-05-2289 |
0.573 |
|
| 2006 |
Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. Journal of Immunology (Baltimore, Md. : 1950). 176: 284-90. PMID 16365420 DOI: 10.4049/Jimmunol.176.1.284 |
0.45 |
|
| 2005 |
Terabe M, Swann J, Ambrosino E, Sinha P, Takaku S, Hayakawa Y, Godfrey DI, Ostrand-Rosenberg S, Smyth MJ, Berzofsky JA. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. The Journal of Experimental Medicine. 202: 1627-33. PMID 16365146 DOI: 10.1084/Jem.20051381 |
0.615 |
|
| 2005 |
Sinha P, Clements VK, Ostrand-Rosenberg S. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Research. 65: 11743-51. PMID 16357187 DOI: 10.1158/0008-5472.Can-05-0045 |
0.529 |
|
| 2005 |
Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Investigation. 23: 413-9. PMID 16193641 DOI: 10.1081/Cnv-200067428 |
0.545 |
|
| 2005 |
Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S. Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression. Cancer Immunology, Immunotherapy : Cii. 54: 1137-42. PMID 15877228 DOI: 10.1007/S00262-005-0703-4 |
0.514 |
|
| 2005 |
Dissanayake SK, Tuera N, Ostrand-Rosenberg S. Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. Journal of Immunology (Baltimore, Md. : 1950). 174: 1811-9. PMID 15699107 DOI: 10.4049/Jimmunol.174.4.1811 |
0.463 |
|
| 2005 |
Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. Journal of Immunology (Baltimore, Md. : 1950). 174: 636-45. PMID 15634881 DOI: 10.4049/Jimmunol.174.2.636 |
0.437 |
|
| 2004 |
Ostrand-Rosenberg S, Sinha P, Danna EA, Miller S, Davis C, Dissanayake SK. Antagonists of tumor-specific immunity: tumor-induced immune suppression and host genes that co-opt the anti-tumor immune response. Breast Disease. 20: 127-35. PMID 15687713 DOI: 10.3233/Bd-2004-20113 |
0.526 |
|
| 2004 |
Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Research. 64: 2205-11. PMID 15026364 DOI: 10.1158/0008-5472.Can-03-2646 |
0.504 |
|
| 2004 |
Ostrand-Rosenberg S. Animal models of tumor immunity, immunotherapy and cancer vaccines. Current Opinion in Immunology. 16: 143-50. PMID 15023405 DOI: 10.1016/J.Coi.2004.01.003 |
0.454 |
|
| 2004 |
Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Research. 64: 1867-74. PMID 14996751 DOI: 10.1158/0008-5472.Can-03-2634 |
0.565 |
|
| 2004 |
Ilkovitch D, Ostrand-Rosenberg S. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain. Cancer Immunology, Immunotherapy : Cii. 53: 525-32. PMID 14730400 DOI: 10.1007/S00262-003-0486-4 |
0.562 |
|
| 2004 |
Dolan BP, Phelan TP, Ilkovitch D, Qi L, Wade WF, Laufer TM, Ostrand-Rosenberg S. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines. Journal of Immunology (Baltimore, Md. : 1950). 172: 907-14. PMID 14707062 DOI: 10.4049/Jimmunol.172.2.907 |
0.576 |
|
| 2004 |
Ostrand-Rosenberg S, Sinha P, Clements V, Dissanayake SI, Miller S, Davis C, Danna E. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunology, Immunotherapy : Cii. 53: 86-91. PMID 14593499 DOI: 10.1007/S00262-003-0446-Z |
0.583 |
|
| 2004 |
Ostrand-Rosenberg S. Introductory comments to Symposium in Writing: Inhibitors of immunosurveillence and anti-tumor immunity Cancer Immunology, Immunotherapy. 53: 63. DOI: 10.1007/S00262-003-0442-3 |
0.435 |
|
| 2003 |
Bécart S, Setterblad N, Ostrand-Rosenberg S, Ono SJ, Charron D, Mooney N. Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling. Journal of Cell Science. 116: 2565-75. PMID 12766188 DOI: 10.1242/Jcs.00449 |
0.353 |
|
| 2003 |
Ostrand-Rosenberg S. Session III: Involvement of HLA-class II molecules in tumor rejection - Activating tumor-specific CD4+ T cells: Tumor cells as antigen-presenting cells and vaccines Cancer Immunology, Immunotherapy. 52. |
0.499 |
|
| 2002 |
Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK. Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. Journal of Immunology (Baltimore, Md. : 1950). 169: 5796-804. PMID 12421960 DOI: 10.4049/Jimmunol.169.10.5796 |
0.489 |
|
| 2002 |
Pulaski BA, Smyth MJ, Ostrand-Rosenberg S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Research. 62: 4406-12. PMID 12154047 |
0.404 |
|
| 2001 |
Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model Current Protocols in Immunology / Edited by John E. Coligan ... [Et Al.]. PMID 18432775 |
0.35 |
|
| 2001 |
Qi L, Ostrand-Rosenberg S. H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens. Journal of Immunology (Baltimore, Md. : 1950). 167: 1371-8. PMID 11466355 DOI: 10.4049/Jimmunol.167.3.1371 |
0.521 |
|
| 2000 |
Qi L, Ostrand-Rosenberg S. MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic (Copenhagen, Denmark). 1: 152-60. PMID 11208095 DOI: 10.1034/J.1600-0854.2000.010207.X |
0.616 |
|
| 2000 |
Ostrand-Rosenberg S, Grusby MJ, Clements VK. Cutting edge: Stat6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma Journal of Immunology. 165: 6015-6019. PMID 11086031 DOI: 10.4049/Jimmunol.165.11.6015 |
0.547 |
|
| 2000 |
Qi L, Rojas JM, Ostrand-Rosenberg S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. Journal of Immunology (Baltimore, Md. : 1950). 165: 5451-61. PMID 11067897 DOI: 10.4049/Jimmunol.165.10.5451 |
0.651 |
|
| 2000 |
Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Research. 60: 2710-5. PMID 10825145 |
0.43 |
|
| 2000 |
Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γ Cancer Immunology Immunotherapy. 49: 34-45. PMID 10782864 DOI: 10.1007/S002620050024 |
0.552 |
|
| 1999 |
Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA. Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunological Reviews. 170: 101-14. PMID 10566145 DOI: 10.1111/J.1600-065X.1999.Tb01332.X |
0.674 |
|
| 1999 |
Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK. Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines. Advances in Experimental Medicine and Biology. 451: 259-64. PMID 10026883 DOI: 10.1007/978-1-4615-5357-1_42 |
0.416 |
|
| 1999 |
Pulaski BA, Clements V, Pipeling M, Ostrand-Rosenberg S. IL-12 SYNERGIZES WITH MHC CLASS II/B7.1-CELL BASED VACCINES T STIMULATE IMMUNE EFFECTORS AND ANTI-ANGIOSTATIC MECHANISM THAT REDUCE ESTABLISHED METASTATIC DISEASE Journla of Immunotherapy. 22: 464. DOI: 10.1097/00002371-199909000-00051 |
0.425 |
|
| 1998 |
Armstrong TD, Clements VK, Ostrand-Rosenberg S. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo Journal of Immunotherapy. 21: 218-224. PMID 9610914 DOI: 10.1097/00002371-199805000-00008 |
0.578 |
|
| 1998 |
Armstrong TD, Pulaski BA, Ostrand-Rosenberg S. Tumor antigen presentation: Changing the rules Cancer Immunology Immunotherapy. 46: 70-74. PMID 9558001 DOI: 10.1007/S002620050463 |
0.595 |
|
| 1998 |
Armstrong TD, Clements VK, Ostrand-Rosenberg S. MHC class II-transfected tumor cells directly present antigen to tumor- specific CD4+ T lymphocytes Journal of Immunology. 160: 661-666. PMID 9551900 |
0.539 |
|
| 1998 |
Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines Cancer Research. 58: 1486-1493. PMID 9537252 |
0.413 |
|
| 1997 |
Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proceedings of the National Academy of Sciences of the United States of America. 94: 6886-91. PMID 9192661 DOI: 10.1073/Pnas.94.13.6886 |
0.455 |
|
| 1996 |
Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK. Expression of MHC class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells Tissue Antigens. 47: 414-421. PMID 8795142 |
0.432 |
|
| 1996 |
Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules Journal of Immunology. 156: 3821-3827. PMID 8621919 |
0.431 |
|
| 1995 |
Baskar S, Glimcher L, Nabavi N, Jones RT, Ostrand-Rosenberg S. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. The Journal of Experimental Medicine. 181: 619-29. PMID 7836917 DOI: 10.1084/Jem.181.2.619 |
0.574 |
|
| 1994 |
Baskar S, Azarenko V, Garcia Marshall E, Hughes E, Ostrand-Rosenberg S. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice Cellular Immunology. 155: 123-133. PMID 8168141 DOI: 10.1006/Cimm.1994.1106 |
0.575 |
|
| 1994 |
Ostrand-Rosenberg S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell Current Opinion in Immunology. 6: 722-727. PMID 7826527 DOI: 10.1016/0952-7915(94)90075-2 |
0.515 |
|
| 1993 |
Baskar S, Nabavi N, Glimcher LH, Ostrand-Rosenberg S. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity Journal of Immunotherapy. 14: 209-215. PMID 8297902 DOI: 10.1097/00002371-199310000-00007 |
0.583 |
|
| 1993 |
Lamousé-Smith E, Clements VK, Ostrand-Rosenberg S. β2M-/- Knockout Mice Contain Low Levels of CD8+ Cytotoxic T Lymphocyte that Mediate Specific Tumor Rejection Journal of Immunology. 151: 6283-6290. PMID 8245467 |
0.489 |
|
| 1993 |
Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules Proceedings of the National Academy of Sciences of the United States of America. 90: 5687-5690. PMID 7685909 DOI: 10.1073/Pnas.90.12.5687 |
0.618 |
|
| 1992 |
Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells Journal of Immunology. 149: 2391-2396. PMID 1527384 |
0.373 |
|
| 1991 |
Ostrand-Rosenberg S, Roby CA, Clements VK. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule Journal of Immunology. 147: 2419-2422. PMID 1918972 |
0.361 |
|
| 1991 |
Nishimura MI, Ostrand-Rosenberg S. Mouse hepa-1 tumor is rejected by H-2db-restricted CTL despite decreased MHC class I antigen expression Cellular Immunology. 136: 414-424. PMID 1908353 DOI: 10.1016/0008-8749(91)90363-G |
0.596 |
|
| 1991 |
Ostrand-Rosenberg S, Roby C, Clements VK, Cole GA. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes. International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement. 6: 61-8. PMID 1906055 |
0.434 |
|
| 1991 |
Cole GA, Ostrand-Rosenberg S. Rejection of allogeneic tumor is not determined by host responses to MHC class I molecules and is mediated by CD4-CD8+ T lymphocytes that are not lytic for the tumor Cellular Immunology. 134: 480-490. PMID 1902400 DOI: 10.1016/0008-8749(91)90319-7 |
0.585 |
|
| 1991 |
Van Kaer L, Wu M, Ichikawa Y, Ito K, Bonneville M, Ostrand-Rosenberg S, Murphy DB, Tonegawa S. Recognition of MHC TL gene products by gamma delta T cells. Immunological Reviews. 120: 89-115. PMID 1830863 DOI: 10.1111/J.1600-065X.1991.Tb00589.X |
0.415 |
|
| 1991 |
Ostrand-Rosenberg S, Garcia EP, Roby CA, Clements VK. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection. Seminars in Cancer Biology. 2: 311-9. PMID 1773047 |
0.427 |
|
| 1990 |
Ostrand-Rosenberg S, Cole GA, Nishimura MI, Clements VK. Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host. Cellular Immunology. 128: 152-64. PMID 2344619 DOI: 10.1016/0008-8749(90)90014-I |
0.454 |
|
| 1990 |
Ostrand-Rosenberg S, Thakur A, Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes Journal of Immunology. 144: 4068-4071. PMID 2332639 |
0.44 |
|
| 1989 |
Ostrand-Rosenberg S, Nickerson DA, Clements VK, Garcia EP, Lamouse-Smith E, Hood L, Stroynowski I. Embryonal carcinoma cells express Qa and Tla class I genes of the major histocompatibility complex. Proceedings of the National Academy of Sciences of the United States of America. 86: 5084-8. PMID 2740345 DOI: 10.1073/Pnas.86.13.5084 |
0.412 |
|
| 1988 |
Nishimura MI, Stroynowski I, Hood L, Ostrand-Rosenberg S. H-2Kb antigen expression has no effect on natural killer susceptibility and tumorigenicity of a murine hepatoma Journal of Immunology. 141: 4403-4409. PMID 3264312 |
0.363 |
|
| 1988 |
Davy CA, Tesfay Z, Jones J, McCarthy C, Ostrand-Rosenberg S, Rosenberg RC. Endogenous superoxide dismutase and catalase activities and radiation resistance in mouse cell lines. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine. 53: 283-9. PMID 3257947 DOI: 10.1080/09553008814550631 |
0.313 |
|
| 1987 |
Cole GA, Cole GA, Clements VK, Garcia EP, Ostrand-Rosenberg S. Allogeneic H-2 antigen expression is insufficient for tumor rejection. Proceedings of the National Academy of Sciences of the United States of America. 84: 8613-7. PMID 3500477 DOI: 10.1073/Pnas.84.23.8613 |
0.453 |
|
| 1987 |
Ostrand-Rosenberg S, Clements V. Resistance to 402AX teratocarcinoma involves immunity to minor histocompatibility antigens Immunogenetics. 26: 1-5. PMID 3301646 DOI: 10.1007/Bf00345447 |
0.496 |
|
| 1986 |
Ostrand-Rosenberg S, Schwartzman ML, Hecht TT, Marr L. Teratocarcinoma cell MHC antigen expression is regulated in vitro by a soluble noninterferon factor Cellular Immunology. 99: 453-460. PMID 3093106 DOI: 10.1016/0008-8749(86)90253-4 |
0.535 |
|
| 1986 |
Ostrand-Rosenberg S, Clements V, Mark L. 402AX teratocarcinoma MHC class I antigen expression is regulated in vivo by Lyt 1, Lyt 2, and L3t4 expressing splenic T cells Cellular Immunology. 98: 257-265. PMID 3093094 DOI: 10.1016/0008-8749(86)90286-8 |
0.538 |
|
| 1984 |
Ostrand-Rosenberg S, Clements V, Cole G, DeCloux A, Marr L, Schwartzman M. Regulation of major histocompatibility gene expression in teratocarcinoma 402AX cells Cell Differentiation. 15: 221-227. PMID 6336034 DOI: 10.1016/0045-6039(84)90078-2 |
0.502 |
|
| 1982 |
Ostrand-Rosenberg S, Cohn A. LYMPHOID CELL REGULATION OF MHC ANTIGEN EXPRESSION ON TERATOCARCINOMA CELLS IN VlVO Annals of the New York Academy of Sciences. 392: 407-407. DOI: 10.1111/j.1749-6632.1982.tb36141.x |
0.362 |
|
| 1981 |
Ostrand-Rosenberg S, Cohan VL. H-2 negative teratocarcinoma cells become H-2 positive when passaged in genetically resistant host mice Journal of Immunology. 126: 2190-2193. PMID 7229370 |
0.311 |
|
| 1981 |
Ostrand-Rosenberg S, Cohn A. H-2 antigen expression on teratocarcinoma cells passaged in genetically resistant mice is regulated by lymphoid cells Proceedings of the National Academy of Sciences of the United States of America. 78: 7106-7110. PMID 7031669 DOI: 10.1073/Pnas.78.11.7106 |
0.482 |
|
| 1980 |
Ostrand-Rosenberg S. Cell-mediated immune responses to mouse embryonic cells: detection and characterization of embryonic antigens Current Topics in Developmental Biology. 14: 147-168. PMID 6450666 DOI: 10.1016/S0070-2153(08)60193-3 |
0.437 |
|
| 1977 |
Ostrand-Rosenberg S, Edidin M, Jewett MAS. Human teratoma cells share antigens with mouse teratoma cells Developmental Biology. 61: 11-19. PMID 72699 DOI: 10.1016/0012-1606(77)90337-2 |
0.405 |
|
| 1977 |
Ostrand-Rosenberg S, Hammerberg C, Edidin M, Sherman MI. Expression of Histocompatibility-2 antigens on cultured cell lines derived from mouse blastocysts Immunogenetics. 4: 127-136. DOI: 10.1007/Bf01575652 |
0.335 |
|
| 1976 |
Ostrand-rosenberg S. Lack of identity of the A antigen and concanavalin A receptor on bovine erythrocytes; implications for membrane structure. Vox Sanguinis. 30: 268-81. PMID 1251591 DOI: 10.1111/J.1423-0410.1976.Tb02827.X |
0.337 |
|
| 1976 |
Ostrand-Rosenberg S. Gene dosage and antigenic expression on the cell surface of bovine erythrocytes. Animal Blood Groups and Biochemical Genetics. 6: 81-99. PMID 56151 DOI: 10.1111/J.1365-2052.1975.Tb01355.X |
0.393 |
|
| 1976 |
Ostrand-Rosenberg S. Topology of bovine red cell antigens as a function of the organization of their genes Immunogenetics. 3: 53-64. DOI: 10.1007/Bf01576938 |
0.327 |
|
| 1975 |
Ostrand-Rosenberg S, Stormont C. Bovine leukocyte antigens. Animal Blood Groups and Biochemical Genetics. 5: 231-7. PMID 4460786 DOI: 10.1111/J.1365-2052.1974.Tb01338.X |
0.315 |
|
| Show low-probability matches. |